- Home
- RVLV vs MIRM Comparison
RVLV vs MIRM Comparison
Compare RVLV & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RVLV
- MIRM
- Stock Information
- Founded
- RVLV 2003
- MIRM 2018
- Country
- RVLV United States
- MIRM United States
- Employees
- RVLV N/A
- MIRM N/A
- Industry
- RVLV Catalog/Specialty Distribution
- MIRM Biotechnology: Pharmaceutical Preparations
- Sector
- RVLV Consumer Discretionary
- MIRM Health Care
- Exchange
- RVLV Nasdaq
- MIRM Nasdaq
- Market Cap
- RVLV N/A
- MIRM 1.9B
- IPO Year
- RVLV 2019
- MIRM 2019
- Fundamental
- Price
- RVLV $19.80
- MIRM $39.10
- Analyst Decision
- RVLV Buy
- MIRM Strong Buy
- Analyst Count
- RVLV 14
- MIRM 11
- Target Price
- RVLV $28.79
- MIRM $58.55
- AVG Volume (30 Days)
- RVLV 1.6M
- MIRM 476.2K
- Earning Date
- RVLV 05-06-2025
- MIRM 05-07-2025
- Dividend Yield
- RVLV N/A
- MIRM N/A
- EPS Growth
- RVLV 81.03
- MIRM N/A
- EPS
- RVLV 0.70
- MIRM N/A
- Revenue
- RVLV $1,129,911,000.00
- MIRM $336,888,000.00
- Revenue This Year
- RVLV $10.98
- MIRM $29.51
- Revenue Next Year
- RVLV $8.77
- MIRM $20.27
- P/E Ratio
- RVLV $28.46
- MIRM N/A
- Revenue Growth
- RVLV 5.73
- MIRM 80.76
- 52 Week Low
- RVLV $14.88
- MIRM $23.14
- 52 Week High
- RVLV $39.58
- MIRM $54.23
- Technical
- Relative Strength Index (RSI)
- RVLV 40.79
- MIRM 34.64
- Support Level
- RVLV $18.29
- MIRM $37.83
- Resistance Level
- RVLV $21.38
- MIRM $40.32
- Average True Range (ATR)
- RVLV 1.68
- MIRM 2.47
- MACD
- RVLV 0.15
- MIRM -0.33
- Stochastic Oscillator
- RVLV 45.14
- MIRM 25.14
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.